Cytosorbents Corp (CTS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytosorbents Corporation on September 27, 2022. The report addresses a specific operational milestone rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory certification event.
Material Changes
On September 27, 2022, the Company announced it received ISO 13485 Certification for its new manufacturing facility located in Princeton, New Jersey. This certification was issued by the Company's European Union (E.U.) notified body.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the context of the certification. The primary event is the successful acquisition of the ISO 13485 standard, which validates the quality management system of the new facility.
Investor Verification Checklist
- Verify the scope of the ISO 13485 certification regarding the Princeton facility's production capabilities.
- Confirm the timeline for full commercial utilization of the newly certified facility.
- Review the attached press release (Exhibit 99.1) for details on how this certification impacts the Company's supply chain or regulatory approvals in the E.U.